LENSAR (LNSR) Competitors $12.10 -0.07 (-0.58%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LNSR vs. BVS, AVNS, ZIMV, KIDS, TMCI, SMLR, CBLL, DCTH, SNWV, and BFLYShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), CeriBell (CBLL), Delcath Systems (DCTH), Sanuwave Health (SNWV), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry. LENSAR vs. Its Competitors Bioventus Avanos Medical ZimVie OrthoPediatrics Treace Medical Concepts Semler Scientific CeriBell Delcath Systems Sanuwave Health Butterfly Network Bioventus (NYSE:BVS) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Which has better earnings & valuation, BVS or LNSR? LENSAR has lower revenue, but higher earnings than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$564.14M1.06-$156.23MN/AN/ALENSAR$53.49M2.70-$31.40M-$4.21-2.87 Does the media prefer BVS or LNSR? In the previous week, Bioventus had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Bioventus and 2 mentions for LENSAR. Bioventus' average media sentiment score of 1.48 beat LENSAR's score of 0.92 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BVS or LNSR? Bioventus presently has a consensus target price of $13.75, indicating a potential upside of 90.58%. LENSAR has a consensus target price of $15.00, indicating a potential upside of 23.98%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75LENSAR 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, BVS or LNSR? Bioventus has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Is BVS or LNSR more profitable? Bioventus has a net margin of -7.11% compared to LENSAR's net margin of -84.49%. Bioventus' return on equity of 15.61% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% LENSAR -84.49%-737.30%-72.60% Do insiders and institutionals believe in BVS or LNSR? 62.9% of Bioventus shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 38.5% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryBioventus beats LENSAR on 11 of the 15 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.46M$6.89B$5.78B$9.92BDividend YieldN/A1.22%6.67%4.51%P/E Ratio-2.8726.4975.8626.67Price / Sales2.7067.81556.21121.26Price / CashN/A21.6037.1158.92Price / Book28.815.0011.436.07Net Income-$31.40M$176.38M$3.29B$266.42M7 Day Performance-1.47%0.06%0.61%0.04%1 Month Performance-7.22%3.72%6.90%3.92%1 Year Performance171.28%11.00%59.44%23.82% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR1.0446 of 5 stars$12.10-0.6%$15.00+24.0%+174.7%$144.46M$53.49M-2.87110BVSBioventus3.3906 of 5 stars$7.44-2.6%$13.75+84.8%-26.5%$615.13M$564.14M-12.201,200Positive NewsAVNSAvanos Medical2.6647 of 5 stars$11.58-1.2%N/A-47.0%$543.37M$687.80M-1.152,227Positive NewsZIMVZimVie0.7223 of 5 stars$18.96+0.1%$17.75-6.4%+12.2%$534.41M$449.75M-27.091,770News CoveragePositive NewsKIDSOrthoPediatrics4.4271 of 5 stars$20.29+0.4%$34.14+68.3%-32.5%$506.49M$204.73M-11.34200News CoveragePositive NewsTMCITreace Medical Concepts2.573 of 5 stars$7.47-3.0%$9.83+31.6%+25.8%$486.43M$209.36M-9.46250Positive NewsAnalyst ForecastSMLRSemler Scientific3.4639 of 5 stars$30.02-4.5%$81.75+172.3%+16.7%$465.32M$42.98M12.35120CBLLCeriBell2.5969 of 5 stars$11.44-5.1%$32.14+181.0%N/A$442.17M$65.44M-3.83N/ADCTHDelcath Systems3.1499 of 5 stars$10.89-2.1%$24.50+125.0%+2.2%$388.99M$70.24M217.8060Positive NewsSNWVSanuwave Health2.78 of 5 stars$42.66-5.2%$55.00+28.9%N/A$385.56M$32.63M-5.1740News CoverageAnalyst ForecastAnalyst RevisionBFLYButterfly Network3.336 of 5 stars$1.56+2.3%$3.00+92.9%-1.0%$382.65M$82.06M-5.55460News CoverageGap Up Related Companies and Tools Related Companies Bioventus Competitors Avanos Medical Competitors ZimVie Competitors OrthoPediatrics Competitors Treace Medical Concepts Competitors Semler Scientific Competitors CeriBell Competitors Delcath Systems Competitors Sanuwave Health Competitors Butterfly Network Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNSR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
